Profile data is unavailable for this security.
About the company
Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).
- Revenue in USD (TTM)0.00
- Net income in USD-22.76m
- Incorporated2020
- Employees14.00
- LocationReviva Pharmaceuticals Holdings Inc10080 N Wolfe Road, Suite Sw3-200CUPERTINO 95014United StatesUSA
- Phone+1 (408) 501-8881
- Fax+1 (408) 904-6270
- Websitehttps://revivapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Raphael Pharmaceutical Inc | 0.00 | -1.40m | 27.48m | 0.00 | -- | -- | -- | -- | -0.0723 | -0.0723 | 0.00 | -0.0644 | 0.00 | -- | -- | -- | -4,831.04 | -- | -- | -- | -- | -- | -- | -- | -- | -86.56 | -- | -- | -- | -- | -13.02 | -- | -- | -- |
| Passage Bio Inc | 0.00 | -45.26m | 27.75m | 60.00 | -- | 0.8917 | -- | -- | -14.47 | -14.47 | 0.00 | 9.79 | 0.00 | -- | -- | 0.00 | -48.69 | -49.32 | -61.70 | -53.58 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 36.54 | -- | -54.23 | -- |
| AN2 Therapeutics Inc | 0.00 | -33.99m | 28.77m | 22.00 | -- | 0.476 | -- | -- | -1.13 | -1.13 | 0.00 | 2.21 | 0.00 | -- | -- | 0.00 | -41.21 | -53.41 | -45.91 | -58.50 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.72 | -- | -- | -- |
| VolitionRX Ltd | 1.47m | -22.88m | 28.88m | 85.00 | -- | -- | -- | 19.62 | -0.229 | -0.229 | 0.0147 | -0.316 | 0.1539 | -- | 4.74 | 17,317.88 | -241.07 | -122.29 | -- | -283.19 | -- | -- | -1,566.40 | -5,826.45 | -- | -15.03 | -- | -- | 59.10 | 135.30 | 23.65 | -- | 2.34 | -- |
| Neurosense Therapeutics Ltd | 0.00 | -8.66m | 29.70m | 15.00 | -- | -- | -- | -- | -0.361 | -0.361 | 0.00 | -0.0211 | 0.00 | -- | -- | 0.00 | -491.23 | -145.64 | -- | -198.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.02 | -- | -15.59 | -- |
| Dyadic International Inc | 3.34m | -7.35m | 29.85m | 6.00 | -- | 11.45 | -- | 8.93 | -0.2371 | -0.2371 | 0.1077 | 0.072 | 0.2974 | -- | 5.27 | 557,033.30 | -65.38 | -46.12 | -89.89 | -51.96 | 31.54 | 35.01 | -219.86 | -335.59 | -- | -34.44 | 0.6579 | -- | 20.58 | 15.77 | 14.51 | -- | -- | -- |
| Reviva Pharmaceuticals Holdings Inc | 0.00 | -22.76m | 29.96m | 14.00 | -- | 5.43 | -- | -- | -0.4722 | -0.4722 | 0.00 | 0.0472 | 0.00 | -- | -- | 0.00 | -207.23 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.79 | -- | -- | -- |
| Lantern Pharma Inc | 0.00 | -18.92m | 30.09m | 24.00 | -- | 3.10 | -- | -- | -1.75 | -1.75 | 0.00 | 0.8684 | 0.00 | -- | -- | 0.00 | -86.16 | -32.94 | -104.31 | -34.72 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.20 | -- | 17.11 | -- |
| Palatin Technologies Inc | 8.85m | -4.81m | 30.16m | 29.00 | -- | 41.45 | -- | 3.41 | -13.52 | -13.52 | 12.39 | 0.4073 | 1.47 | -- | -- | 305,087.90 | -79.90 | -79.95 | -- | -118.70 | 0.00 | 91.70 | -54.32 | -1,326.05 | -- | -- | 0.00 | -- | -100.00 | -- | 41.80 | -- | -- | -- |
| Tempest Therapeutics Inc | 0.00 | -36.05m | 30.48m | 24.00 | -- | 1.62 | -- | -- | -10.40 | -10.40 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -141.49 | -63.01 | -215.46 | -80.57 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -41.88 | -- | 1.85 | -- |
| Rein Therapeutics Inc | 0.00 | -58.89m | 30.76m | 11.00 | -- | 24.82 | -- | -- | -2.63 | -2.63 | 0.00 | 1.84 | 0.00 | -- | -- | 0.00 | -74.57 | -64.62 | -80.38 | -71.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -299.71 | -- | -- | -- |
| Werewolf Therapeutics Inc | 0.00 | -72.84m | 31.99m | 39.00 | -- | 1.05 | -- | -- | -1.62 | -1.62 | 0.00 | 0.6264 | 0.00 | -- | -- | 0.00 | -66.32 | -33.10 | -76.84 | -36.81 | -- | -- | -- | -593.05 | -- | -54.29 | 0.4829 | -- | -90.55 | -- | -88.70 | -- | -0.919 | -- |
| Atara Biotherapeutics Inc | 151.93m | 23.40m | 32.09m | 38.00 | 2.03 | -- | 1.21 | 0.2112 | 2.19 | 2.19 | 12.81 | -5.08 | 1.76 | 3.99 | 93.55 | 993,006.60 | 27.07 | -67.79 | -- | -93.07 | 81.63 | -- | 15.40 | -558.47 | 1.02 | 15.24 | 8.31 | -- | 1,404.02 | -- | 69.07 | -- | -46.73 | -- |
| Harvard Apparatus Regenertv Tchnlgy Inc | 743.00k | -6.53m | 32.16m | 8.00 | -- | 20.69 | -- | 43.28 | -0.4029 | -0.4029 | 0.0459 | 0.0905 | 0.1891 | 9.21 | 371.50 | 92,875.00 | -166.09 | -292.39 | -227.59 | -1,068.06 | 16.29 | -- | -878.20 | -6,677.86 | 1.83 | -- | 0.00 | -- | 317.48 | -- | 14.30 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -29.28m | 32.20m | 6.00 | -- | 3.50 | -- | -- | -18.62 | -18.62 | 0.00 | 4.27 | 0.00 | -- | -- | -- | -127.41 | -85.65 | -188.18 | -145.08 | -- | -- | -- | -3,184,250.00 | -- | -- | 0.00 | -- | -- | -- | 121.03 | -- | -- | -- |
| Outlook Therapeutics Inc | 1.51m | -62.42m | 32.42m | 17.00 | -- | -- | -- | 21.54 | -1.61 | -1.61 | 0.0432 | -0.5973 | 0.0635 | -- | -- | 88,548.23 | -263.36 | -240.08 | -- | -- | 70.78 | -- | -4,146.95 | -22,354.50 | 0.3067 | -200.54 | -- | -- | -- | -- | 17.17 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Reviva Pharmaceuticals Holdings Inc's reporting currency: US Dollar USD
10.18%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Millennium Management LLCas of 31 Dec 2025 | 3.26m | 2.83% |
| Diadema Partners LPas of 30 Sep 2025 | 2.51m | 2.18% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.50m | 2.18% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 631.92k | 0.55% |
| Abante Asesores Gesti�n SGIIC SAas of 31 Dec 2025 | 609.64k | 0.53% |
| Persistent Asset Partners Ltd.as of 30 Sep 2025 | 593.90k | 0.52% |
| Geode Capital Management LLCas of 30 Sep 2025 | 559.24k | 0.49% |
| Susquehanna Financial Group LLLPas of 30 Sep 2025 | 524.05k | 0.46% |
| UBS Securities LLCas of 31 Dec 2025 | 303.68k | 0.26% |
| Jane Street Capital LLCas of 30 Sep 2025 | 228.13k | 0.20% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
